Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China

Microb Drug Resist. 2014 Aug;20(4):294-300. doi: 10.1089/mdr.2013.0145. Epub 2013 Dec 13.

Abstract

Setting: Multidrug-resistant tuberculosis (MDR-TB) has emerged as a serious global public health problem. In China, the risk factors for MDR-TB have not been systematically evaluated.

Objective: To identify risk factors associated with MDR-TB among previously treated patients in China.

Design: A case-control study was carried out. Cases were selected from previously treated MDR-TB patients who were resistant to both isoniazid and rifampin, and controls were selected from previously treated TB patients who were sensitive to isoniazid and rifampin (non-MDR-TB). Information was collected from the registration database and a structured questionnaire.

Results: A total of 61 cases and 50 controls were recruited. A multivariate analysis showed that the family annual per-capita income ≤7,000 Yuan (odds ratio [OR]=3.238; 95% confidence interval [CI]: 1.270-8.252), no history of fixed dose combinations (FDCs) in anti-TB treatment (OR=4.027; 95% CI: 1.457-11.129), and adverse reactions in the course of TB treatment (OR=3.568; 95% CI: 1.402-9.085) were independent predictors of MDR-TB. Moreover, among the TB patients who had adverse reactions, quitting the treatment was shown as a risk factor for MDR-TB (p=0.009).

Conclusion: In the control of MDR-TB among previously treated patients, lower socioeconomic groups, the expanding use of FDCs, and improving adherence to treatment by implementing Directly Observed Therapy Short Course-Plus (DOTS-Plus), strictly should become a priority that requires strong commitment and collaboration among health organizations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antitubercular Agents / therapeutic use*
  • Case-Control Studies
  • China
  • Drug Resistance, Multiple, Bacterial*
  • Female
  • Humans
  • Income
  • Isoniazid / therapeutic use*
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / pathogenicity
  • Mycobacterium tuberculosis / physiology
  • Patient Compliance / psychology
  • Rifampin / therapeutic use*
  • Risk Factors
  • Surveys and Questionnaires
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / economics
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Tuberculosis, Multidrug-Resistant / psychology
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / economics
  • Tuberculosis, Pulmonary / microbiology
  • Tuberculosis, Pulmonary / psychology

Substances

  • Antitubercular Agents
  • Isoniazid
  • Rifampin